Posted by Michael Wonder on 21 Oct 2020
Xeris Pharmaceuticals granted fast track designation by the FDA for its novel concentrated diazepam formulation (XP-0863) for injection
20 October 2020 - Xeris Pharmaceuticals today announced it was granted fast track designation by the FDA for the investigation of XP-0863 (diazepam non-aqueous injection) for the treatment of acute repetitive seizures.
Xeris’ XP-0863 was previously granted orphan designations both for the treatment of acute repetitive seizures and for the treatment of Dravet syndrome.
